In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.

ABSTRACT:

SUBMITTER: Laukkanen S 

PROVIDER: S-EPMC5709756 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature